<DOC>
	<DOCNO>NCT01044745</DOCNO>
	<brief_summary>This phase II trial study well rituximab work prevent acute graft-versus-host disease ( GVHD ) patient undergo donor stem cell transplant hematologic cancer . Giving chemotherapy total-body irradiation donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving monoclonal antibody , rituximab , together anti-thymocyte globulin , tacrolimus , mycophenolate mofetil transplant may stop happen</brief_summary>
	<brief_title>Rituximab Preventing Acute Graft-Versus-Host Disease Patients Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine incidence grade II-IV acute GVHD day 100 match unrelated donor allogeneic hematopoietic cell transplantation ( HCT ) incorporate rituximab condition regimen . SECONDARY OBJECTIVES : I . To determine day 100 transplant relate mortality match unrelated donor allogeneic HCT incorporate rituximab condition regimen . II . To determine overall survival ( OS ) disease-free survival ( DFS ) match unrelated donor allogeneic HCT incorporate rituximab condition regimen . III . To determine cumulative incidence infectious complication day 100 match unrelated donor HCT incorporate rituximab condition regimen . IV . To determine effect rituximab addition condition regimen recovery T regulatory ( T-reg ) cell , determine effect T-cell , include T-reg , number stem cell product day 30 incidence grade II-IV acute GVHD ( aGVHD ) cumulative infectious complication day 100 . V. To determine effect rituximab addition condition regimen antigen present myeloid cell recovery , determine effect dendritic cell subset DC1 , DC2 myeloid-derived suppressor cell ( MDSC ) , number stem cell graft day +30 incidence acute GVHD grade II-IV cumulative incidence infectious complication day 100 . OUTLINE : CONDITIONING REGIMEN : Patients receive one follow conditioning regimen per transplant physician : cyclophosphamide total-body irradiation ( TBI ) ; target busulfan fludarabine ; reduced-dose busulfan fludarabine ; fludarabine TBI . GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS : Patients receive rituximab intravenously ( IV ) day -6 , 1 , 8 , 15 anti-thymocyte globulin IV 6-8 hour day -3 -1 . Patients also receive tacrolimus IV continuously orally ( PO ) begin day -1 continue day 150 follow taper day 180 mycophenolate mofetil PO IV twice daily day -1 60 . TRANSPLANTATION : Patients undergo allogeneic hematopoietic stem cell transplantation day 0 . Patients follow periodically 100 day transplant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , chronic myelogenous leukemia ( CML ) accelerate phase blast crisis , chronic lymphocytic leukemia ( CLL ) , NonHodgkin lymphoma ( NHL ) , myelodysplastic syndrome ( MDS ) ( intermediate2 highrisk disease International Pelvic Pain Society [ IPPS ] ) Patients AML , ALL , MDS schedule myeloablative conditioning = &lt; 10 % blast bone marrow peripheral blood start conditioning Patients AML , ALL , CML schedule reduce intensity condition nonmyeloablative conditioning complete morphologic remission start conditioning ( residual disease flow cytometry cytogenetics and/or incomplete recovery neutrophil platelet count acceptable ) Patients CLL NHL schedule reduce intensity nonmyeloablative conditioning evidence bulky disease ( &gt; 50 % bone marrow involvement mass &gt; 10 cm ) start condition Fulfills pulmonary , cardiac , renal , hepatic criterion standardofcare match unrelated donor ( MUD ) allogeneic HCT Men woman reproductive potential must agree use acceptable method birth control treatment twelve month stem cell transplantation Adequately match unrelated donor available Written inform consent ; write informed consent unrelated donor require participate optional study Patient donor infect human immunodeficiency virus ( HIV ) Patient donor history hepatitis B C and/or positive serology consistent previous hepatitis B C infection ( patient and/or donor receive Hepatitis B vaccination acceptable ) Patient donor active hepatitis B C and/or detectable viral ribonucleic acid ( RNA ) More 20,000 circulate CD20+ cells/uL Treatment rituximab reason 12 month precede HCT Patient schedule cord blood transplantation Presence active uncontrolled infection start condition Presence active central nervous system ( CNS ) disease ( history adequately treat CNS disease acceptable ) Presence uncontrolled psychiatric disorder Patient unable give inform consent Unrelated donor product receive Deutsche Knochenmarkspenderdatei ( DKMS ) Registry eligible optional study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>